The pharmaceutical firm's consolidated net profit slipped 1.5% to Rs 119.28 crore on 3.7% increase in net sales to Rs 745.10 crore in Q1 FY23 over Q1 FY22.
Profit before tax (PBT) from continuing operations for the first quarter was Rs 160.03 crore, recording a growth of 9.5% YoY.Total expenses rose 1.8% YoY to Rs 596.18 crore in Q1 FY23. Cost of raw materials declined 15.3% to Rs 153.78 crore in Q1 FY23 over Q1 FY22.
Sridhar Venkatesh, managing director, GlaxoSmithKline Pharmaceuticals, said, "Our results reflect good momentum across general medicines and vaccines during the quarter. We have delivered strong underlying growth with market share gains across focus brands. Our vaccines business has maintained leadership in the self-pay segment while the overall vaccines market continues to be in decline.
During the quarter, we launched one of our innovative products, Trelegy Ellipta the first single-inhaler triple therapy (SITT) in India for Chronic Obstructive Pulmonary Disease (COPD) patients in a once-daily regime for patients aged 18 and above. With this launch, we are enabling Indian COPD patients to benefit from this world-leading medicine. We expect to build on this momentum as we continue to invest in our focus brands to drive growth."
GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies.
The scrip rose 0.07% to currently trade at Rs 1,494.95 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app